126 related articles for article (PubMed ID: 12821360)
1. Phase II evaluation of oxaliplatin in previously treated squamous cell carcinoma of the cervix: a gynecologic oncology group study.
Fracasso PM; Blessing JA; Wolf J; Rocereto TF; Berek JS; Waggoner S
Gynecol Oncol; 2003 Jul; 90(1):177-80. PubMed ID: 12821360
[TBL] [Abstract][Full Text] [Related]
2. Phase II study of oxaliplatin as second-line chemotherapy in endometrial carcinoma: a Gynecologic Oncology Group study.
Fracasso PM; Blessing JA; Molpus KL; Adler LM; Sorosky JI; Rose PG
Gynecol Oncol; 2006 Nov; 103(2):523-6. PubMed ID: 16712905
[TBL] [Abstract][Full Text] [Related]
3. A phase II study of carboplatin in advanced squamous cell carcinoma of the cervix (a Gynecologic Oncology Group Study).
Arseneau J; Blessing JA; Stehman FB; McGehee R
Invest New Drugs; 1986; 4(2):187-91. PubMed ID: 3525449
[TBL] [Abstract][Full Text] [Related]
4. Phase II clinical trial of docetaxel in refractory squamous cell carcinoma of the cervix: a Gynecologic Oncology Group Study.
Garcia AA; Blessing JA; Vaccarello L; Roman LD;
Am J Clin Oncol; 2007 Aug; 30(4):428-31. PubMed ID: 17762444
[TBL] [Abstract][Full Text] [Related]
5. A phase II study of CHIP in advanced squamous cell carcinoma of the cervix (a Gynecologic Oncology Group Study).
McGuire WP; Blessing JA; Hatch K; DiSaia PJ
Invest New Drugs; 1986; 4(2):181-6. PubMed ID: 3733378
[TBL] [Abstract][Full Text] [Related]
6. Phase II study of oxaliplatin in platinum-resistant and refractory ovarian cancer: a gynecologic group study.
Fracasso PM; Blessing JA; Morgan MA; Sood AK; Hoffman JS
J Clin Oncol; 2003 Aug; 21(15):2856-9. PubMed ID: 12885801
[TBL] [Abstract][Full Text] [Related]
7. A randomized comparative trial of carboplatin and iproplatin in advanced squamous carcinoma of the uterine cervix: a Gynecologic Oncology Group study.
McGuire WP; Arseneau J; Blessing JA; DiSaia PJ; Hatch KD; Given FT; Teng NN; Creasman WT
J Clin Oncol; 1989 Oct; 7(10):1462-8. PubMed ID: 2674333
[TBL] [Abstract][Full Text] [Related]
8. Prolonged oral etoposide in recurrent or advanced squamous cell carcinoma of the cervix: a gynecologic oncology group study.
Rose PG; Blessing JA; Van Le L; Waggoner S
Gynecol Oncol; 1998 Aug; 70(2):263-6. PubMed ID: 9740702
[TBL] [Abstract][Full Text] [Related]
9. Cisplatin and pentoxifylline in advanced or recurrent squamous cell carcinoma of the cervix: a phase II trial of the Gynecologic Oncology Group.
Mannel RS; Blessing JA; Boike G
Gynecol Oncol; 2000 Oct; 79(1):64-6. PubMed ID: 11006033
[TBL] [Abstract][Full Text] [Related]
10. A phase II trial of gallium nitrate (NSC #15200) in advanced or recurrent squamous cell carcinoma of the cervix. A Gynecologic Oncology Group study.
Malfetano JH; Blessing JA; Homesley HD; Hanjani P
Invest New Drugs; 1991 Feb; 9(1):109-11. PubMed ID: 2026479
[TBL] [Abstract][Full Text] [Related]
11. Phase II trial of topotecan and cisplatin in persistent or recurrent squamous and nonsquamous carcinomas of the cervix.
Fiorica J; Holloway R; Ndubisi B; Orr J; Grendys E; Boothby R; DeCesare S; LaPolla J; Hoffman M; Patel J
Gynecol Oncol; 2002 Apr; 85(1):89-94. PubMed ID: 11925125
[TBL] [Abstract][Full Text] [Related]
12. A Phase II study of topotecan in patients with squamous cell carcinoma of the cervix: a gynecologic oncology group study.
Muderspach LI; Blessing JA; Levenback C; Moore JL
Gynecol Oncol; 2001 May; 81(2):213-5. PubMed ID: 11354055
[TBL] [Abstract][Full Text] [Related]
13. Topotecan in squamous cell carcinoma of the cervix: A Phase II study of the Gynecologic Oncology Group.
Bookman MA; Blessing JA; Hanjani P; Herzog TJ; Andersen WA
Gynecol Oncol; 2000 Jun; 77(3):446-9. PubMed ID: 10831357
[TBL] [Abstract][Full Text] [Related]
14. N-Methylformamide in advanced squamous cancer of the uterine cervix: an Eastern Cooperative Oncology Group phase II trial.
Rajdev L; Yu ZF; Wadler S; Weller E; Kahn SB; Tormey D; Skeel R; Wiernik PH
Invest New Drugs; 2001; 19(3):233-7. PubMed ID: 11561680
[TBL] [Abstract][Full Text] [Related]
15. Phase II trial of cetuximab in the treatment of persistent or recurrent squamous or non-squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study.
Santin AD; Sill MW; McMeekin DS; Leitao MM; Brown J; Sutton GP; Van Le L; Griffin P; Boardman CH
Gynecol Oncol; 2011 Sep; 122(3):495-500. PubMed ID: 21684583
[TBL] [Abstract][Full Text] [Related]
16. A phase II trial of JM-216 in cervical cancer: an NCIC CTG study.
Trudeau M; Stuart G; Hirte H; Drouin P; Plante M; Bessette P; Dulude H; Lebwohl D; Fisher B; Seymour L
Gynecol Oncol; 2002 Feb; 84(2):327-31. PubMed ID: 11812095
[TBL] [Abstract][Full Text] [Related]
17. A phase II trial of didemnin B (NSC #335319) in patients with advanced squamous cell carcinoma of the cervix. A Gynecologic Oncology Group Study.
Malfetano JH; Blessing JA; Homesley HD; Look KY; McGehee R
Am J Clin Oncol; 1996 Apr; 19(2):184-6. PubMed ID: 8610646
[TBL] [Abstract][Full Text] [Related]
18. Phase II experience with ifosfamide/mesna in gynecologic malignancies: preliminary report of Gynecologic Oncology Group studies.
Sutton GP; Blessing JA; Photopulos G; Berman ML; Homesley HD
Semin Oncol; 1989 Feb; 16(1 Suppl 3):68-72. PubMed ID: 2539647
[TBL] [Abstract][Full Text] [Related]
19. Oxaliplatin salvage for recurrent ovarian cancer: a single institution's experience in patient populations with platinum resistant disease or a history of platinum hypersensitivity.
Taylor SE; Beck TL; Krivak TC; Zorn KK; Kelley JL; Edwards RP
Gynecol Oncol; 2014 Jul; 134(1):68-72. PubMed ID: 24769036
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of pegylated liposomal doxorubicin (Doxil) as second-line chemotherapy of squamous cell carcinoma of the cervix: a phase II study of the Gynecologic Oncology Group.
Rose PG; Blessing JA; Lele S; Abulafia O
Gynecol Oncol; 2006 Aug; 102(2):210-3. PubMed ID: 16478630
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
